Well Health Technologies Doubles Down on AI and Clinics

Well Health Technologies ((TSE:WELL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Well Health Technologies’ latest earnings call painted a notably upbeat picture, with management emphasizing strong revenue growth, expanding margins and rising clinic productivity. Executives acknowledged pressure from higher capital spending and weaker free cash flow, yet framed these as deliberate, temporary investments that underpin reaffirmed 2026 targets and a strategy increasingly anchored in Canadian primary care and AI-driven efficiency.

Strong Top-Line Growth and Reaffirmed Revenue Targets

Well Health posted Q1 revenue of $368.3 million, up 25% year over year from $294 million, as both clinics and software platforms contributed to the expansion. Management reaffirmed its fiscal 2026 revenue outlook of $1.55 billion to $1.65 billion, implying reported growth of 11% to 18% and normalized growth of 16% to 22% when excluding Circle Medical’s deferred revenue.

Margin and Profitability Expansion

Profitability metrics moved sharply higher, with adjusted EBITDA rising 56% year over year to $43.1 million and adjusted net income nearly doubling to $15.5 million. Adjusted gross profit climbed 39% to $163.2 million, lifting adjusted gross margin by 440 basis points to 44.3%, underscoring operating leverage despite heavier investment.

Canadian Clinics: High Growth and Better Margins

Canadian clinics delivered $130.3 million in Q1 revenue and are on pace to materially exceed $500 million in 2026, reinforcing Canada as the company’s growth core. This segment generated $17 million of adjusted EBITDA, up 28% year over year, with primary care margins improving to roughly 8% from 6.2%, supported by a four-year revenue CAGR of about 47% and EBITDA CAGR of 44%.

Operational Scale and Productivity Gains

System-wide patient visits reached 1.9 million in Q1, up 17% year over year, with Canadian visits around 1.3 million growing more than 30%. Billable providers in Canada increased 17% to 2,204, and visits per provider rose roughly 14% to 576, indicating meaningful productivity gains helped by AI tools and digital workflows.

Wellstar SaaS Momentum

Wellstar, the company’s SaaS arm, generated $21.8 million in Q1 revenue, up 27% year over year, with monthly recurring revenue advancing 38% to $6.4 million. Adjusted EBITDA reached $4.9 million, up 14%, and would have been about $5.2 million and up 20% excluding spinout-related costs, highlighting durable software economics.

Healwell’s Rapid Scale and Turnaround

Healwell’s top line surged to $33.2 million, a striking 316% year-over-year increase reflecting aggressive expansion and new customers. The unit swung to positive adjusted EBITDA of $0.7 million from a $2.3 million loss a year ago, signalling rapid margin recovery across its international footprint, including clients across 11 countries.

AI-Enabled Product and Operational Wins

The company stressed its AI-led productivity push, noting that it transcribed and mobilized data from 195,000 fax images in Q1, with physicians reportedly saving up to 10 hours per week through AI transcription. Healwell screened more than 59,000 patient records for disease signals, while Wellstar’s billing platform surpassed a $1 billion annualized physician pay run rate and maintained an NPS near 80.

New Strategic Platforms and Growth Initiatives

Well Health launched its Health Intelligence Platform to unify data and accelerate AI deployment, targeting cost optimization across the network. The company also rolled out Well Research to consolidate clinical research assets and shift toward higher-margin Phase I trials, and combined cybersecurity capabilities into CyberWell, where it plans to bring in external capital partners.

Balance Sheet Strength and Liquidity Expansion

The company ended the quarter with $134 million in cash and an expanded senior secured facility of CAD 400 million plus a CAD 100 million accordion, with maturities extended to 2030. Management highlighted this doubled lending capacity, alongside continued share buybacks under its NCIB, as key supports for its M&A-driven growth strategy.

Large M&A Pipeline and Capital Allocation Focus

Well Health reported an M&A pipeline exceeding $440 million of annual revenue across more than 50 targets and over 125 clinics, with about $265 million of Canadian clinic revenue in advanced discussions. The company reiterated that capital will be directed primarily toward Canadian clinics, while pursuing strategic alternatives for non-core platforms such as Wellstar, U.S. assets and CyberWell.

Circle Medical Compliance and Deferred Revenue

Circle Medical posted Q1 revenue of $36 million, up 21% year over year, including $12.8 million of previously deferred revenue recognized in the quarter. Management noted a year-over-year decline in Circle patient visits due to heightened compliance efforts and expects only about $4.8 million of deferred revenue to be recognized in Q2, with no further deferrals thereafter amid ongoing regulatory uncertainty.

Capex Surge and Free Cash Flow Pressure

Capital expenditures jumped 88% year over year in Q1, driven by Healwell integration, clinic upgrades and investments in Well Research, CyberWell and the intelligence platform. These growth projects contributed to a drop in operating adjusted free cash flow attributable to shareholders to $1.6 million from $11.8 million, a sharp decline that management framed as a temporary trade-off.

U.S. Assets Under Review and Performance Challenges

The company’s U.S. portfolio remains under strategic review, introducing uncertainty around timing and outcomes for businesses such as Wisp, Circle Medical and CRH. Wisp’s revenue was roughly flat at $29.1 million with a $0.9 million adjusted EBITDA loss, while CRH revenue slipped modestly to $111.3 million, reflecting staffing volatility and weaker performance.

Investment-Driven Margin Pressure and Execution Risk

Near-term profitability has been constrained by spending on Well Research, CyberWell and the AI platform, which depress current free cash flow. Management is betting that these initiatives will expand margins over time, but acknowledged the execution risk if benefits arrive later than expected or integration proves more complex.

Dependence on Deferred Revenue and M&A Integration

The company’s guidance includes approximately $17.6 million of Circle Medical deferred revenue with nearly full EBITDA contribution, which heightens sensitivity to timing and comparability. Management also highlighted the operational challenge of integrating more than $440 million of potential M&A, noting past limits on clinic absorption and the need to scale transformation teams to avoid overextension.

Guidance and Outlook

Well Health reaffirmed its 2026 outlook for $1.55 billion to $1.65 billion in revenue and $175 million to $185 million in adjusted EBITDA, including the remaining Circle deferrals but only announced deals. Management expects Circle-related deferrals to largely roll off in 2026, targets more than 10% annual growth in adjusted EBITDA and free cash flow, and is aiming for its Canadian operations to reach about $800 million in revenue and over $100 million of adjusted EBITDA within roughly a year, helped by a cost-optimization push in the second half.

Well Health’s earnings call ultimately balanced confidence with candor, as strong growth in Canadian clinics, SaaS and AI-enabled operations contrasted with weaker U.S. assets and near-term cash strain. For investors, the story hinges on whether management can convert its heavy investment cycle and ambitious M&A pipeline into sustained margin expansion and cash generation without stumbling on compliance, integration or execution risks.